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Abstract 
 
THE ROLE OF BRCA1 IN DNA DOUBLE-STRAND BREAK REPAIR 
By: Seth Michael Dever, B.A. 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy in Biochemistry and Molecular Biology at Virginia Commonwealth 
University. 
 
Virginia Commonwealth University, 2009 
 
Major Director: Kristoffer Valerie 
Professor, Department of Radiation Oncology 
 
 
Mutations in the breast cancer susceptibility 1 (BRCA1) gene are linked to breast as well 
as ovarian cancers.  However, most cancer-causing mutations within the BRCA1 gene 
have been found in the N and C terminal regions of the BRCA1 protein, both believed 
to be important for DNA double-strand break (DSB) repair.  The BRCA1 C terminal 
(BRCT) repeats have been implicated in phospho-serine protein binding whereas the N 
terminal RING domain interacts with the BARD1 protein to form a hetero-dimeric 
complex with E3 ubiquitin ligase activity.  The BRCA1 BRCT domain binds CtIP, 
BACH1, and RAP80, all of which have been directly implicated in homologous 
recombination repair (HRR).  Lysine 1702 (K1702) of BRCA1 resides within the 
phospho-serine binding pocket of the first BRCT repeat of BRCA1.  To determine the 
effect of manipulating the ability of BRCA1 to bind CtIP and other phospho-proteins 
binding to the BRCA1 BRCT domain on DSB repair, and specifically HRR, we 
introduced a K1702M mutation into BRCA1 known to impair BRCT binding to a pSer-
X-X-Phe peptide representing BACH1.  Surprisingly, instead of impairing HRR, we 
 xii
found that BRCA1 K1702M resulted in hyper-recombination with > 3-fold higher levels 
of HRR compared to wild-type BRCA1 using an HRR assay based on GFP expression in 
BRCA1-defective HCC1937 cells.  This hyper-recombinogenic phenotype coincided 
with cell-cycle arrest in S/G2 suggesting that the potential lack of binding of critical 
proteins to the BRCA1 BRCT domain results in abnormal HRR by priming cells to 
undergo more HRR which is enhanced during the S and G2 phases of the cell-cycle.  In 
line with the increased HRR seen with the HRR/GFP assay, HCC1937 cells expressing 
BRCA1 K1702M showed increased levels of RAD51 foci and nuclear staining 
suggesting that HRR was highly elevated.  Interestingly, the hyper-recombinogenic 
phenotype of BRCA1 K1702M could be reduced to normal levels with a second mutation 
(I26A) in BRCA1 that affects BRCA1 and CtIP ubiquitination.  These results reveal a 
hierarchal regulation of HRR with ubiquitination having a dominate role in DSB repair 
by BRCA1 and suggests that targeted disruption of BRCT-CtIP binding increases HRR 
that is in turn controlled by ubiquitination.  In addition, we provide evidence that BRCA1 
serine 1387 phosphorylation within the SQ cluster region of BRCA1 is involved in the 
cell survival and DNA damage response to IR.  The BRCA1 S1387A mutant only 
partially increased the radiosurvival of HCC1937 cells compared to cells expressing 
wild-type BRCA1 and immunocytochemical analysis revealed wild-type BRCA1 was 
located in the nucleus whereas the S1387A mutant was cytoplasmic in response to IR.  
We also show that BRCA1 SQ cluster serine phosphorylation in addition to serine 1387 
is involved in HRR.  Altogether, these findings reveal the importance of various regions 
of BRCA1 in DSB repair and may lead to multiple strategies of modulating BRCA1 
function in response to DNA damage.    
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Chapter 1:  Introduction 
 
BRCA genes and breast cancer 
 
Despite much research into and awareness of breast cancer, it still remains a formidable 
disease.  Breast cancer is an inherited disease in 5-10% of cases while the other 90-95% 
are sporadic (Rosen et al. 2003).  A major breakthrough in discovering the cause of 
hereditary breast cancer came in 1994 with the discovery of the breast and ovarian cancer 
susceptibility gene 1 (BRCA1) and again in 1995 with the discovery of the BRCA2 gene 
(Miki et al. 1994) (Wooster et al. 1995).  BRCA1 was localized to chromosome 17q and 
BRCA2 to 13q.  These discoveries set the basis for a genetic link to breast cancer as well 
as ways to screen for breast cancer susceptibility.  Research into the functions of the 
protein products of these two genes lead to the discovery that both of these proteins 
participate in the homology-directed repair of DNA double-strand breaks (DSBs) 
(Moynahan et al. 1999) (Moynahan et al. 2001).  Thus, it appears that genetic mutations 
that disrupt the repair capacities of these proteins may be a major influence in the 
development of breast and ovarian cancers.   
 
The BRCA1 protein 
 
Although both BRCA1 and BRCA2 have been implicated in homologous recombination, 
BRCA1 appears to have more diverse roles in the cell than BRCA2.  BRCA1 is a 
relatively large protein spanning 1863 amino acids.  The BRCA1 amino (N’) terminus 
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contains a really interesting new gene (RING) domain while the carboxyl (C’) terminus 
consists of two tandem BRCA1 C’ terminal (BRCT) repeats.  Between the central and C’ 
terminal region is the serine-glutamine (SQ) cluster (Fig. 1).   
 
 
 
Figure 1.  Representation of the BRCA1 polypeptide.  The BRCA1 protein spans 1863 
amino acids.  At the N’ terminus is the RING domain which has associated ubiquitin 
ligase activity while the C’ terminus contains two tandem BRCT repeats involved in 
phospho-protein binding.  The intervening SQ cluster is the site of phosphorylation by the 
DNA-damage sensors ATM and ATR. 
 
 
The N’ terminal RING domain has E3 ubiquitin ligase activity and forms a heterodimeric 
complex with another RING domain containing protein BARD1 (Wu et al. 1996).  
Together, these two proteins constitute a fully active E3 ubiquitin ligase complex 
(Hashizume et al. 2001).  The ubiquitin ligase activity autoubiquitinates BRCA1 using an 
unconventional lysine 6 linkage and autoubiquitination has been shown to increase the 
ubiquitin ligase activity of BRCA1 (Wu-Baer et al. 2003) (Nishikawa et al. 2004) 
(Mallery et al. 2002).  Interestingly, the BRCA1-BARD1 interaction also seems to 
localize this complex in the nucleus by masking the BRCA1 nuclear export signals 
(NESs) (Fabbro et al. 2002) (Rodriguez et al. 2004).  BRCA1 has two nuclear 
localization signals (NLSs) and two NESs (Chen et al. 1996) (Rodriguez and Henderson 
2000) (Thompson et al. 2005).  The NESs are located at amino acids 22-30 and 81-99 and 
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the NLSs from amino acids 503-508 and 606-615.   Thus, the masking of the N’ terminal 
NESs by BARD1 would localize BRCA1 in the nucleus with maximal ubiquitin ligase 
activity.  In addition to ubiquitinating itself, BRCA1 also ubiquitinates the BRCA1 
BRCT domain binding protein CtIP (Yu et al. 2006).   
 
The BRCA1 BRCT domain binds phospho-proteins containing the phospho-serine-X-X-
phenylalanine (pSer-X-X-Phe) motif, X representing any amino acid (Yu et al. 2003) 
(Manke et al. 2003).  There are three known phospho-proteins the BRCA1 BRCT domain  
interacts with forming three mutually exclusive complexes termed complex A for 
Abraxus (CCDC98), B for BACH1, and C for CtIP (Yu and Chen 2004) (Cantor et al. 
2001) (Wang et al. 2007).  Abraxas bridges another protein, RAP80, to BRCA1 and 
interestingly RAP80, BACH1, and CtIP have all been shown to be directly involved in 
the homology-directed repair of DSBs (Sartori et al. 2007) (Litman et al. 2005) (Yan et 
al. 2007).  RAP80 localizes BRCA1 to the site of DSBs through its ubiquitin interacting 
motifs which interact with ubiquitinated H2AX while the BACH1 helicase has been 
found to be involved in S-phase progression (Sobhian et al. 2007) (Kumaraswamy and 
Shiekhattar 2007).  However, of the three BRCA1 BRCT domain interacting proteins, 
CtIP is uniquely ubiquitinated by BRCA1 and is involved in G2/M cell-cycle arrest (Yu, 
Fu et al. 2006).  In addition to its role in binding phospho-proteins directly involved in 
homologous recombination, the BRCA1 BRCT domain also functions in transcription on 
the p21 promoter through its association with p53 and dissociation with CtIP (Ouchi et al. 
1998) (Zhang et al. 1998) (Chai et al. 1999) (Li et al. 1999).  The dissociation of CtIP 
upon DNA damage might allow p53 binding leading to transcriptionally-mediated cell-
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cycle arrest and DSB repair.  BRCA1 has also been found to associate with the 
acetyltransferase complex CBP/p300 which could further increase BRCA1-p53 
dependent transcriptional activity (Pao et al. 2000).   
 
The multiple roles and binding partners of the BRCA1 BRCT domain stress its 
importance in the tumor suppressor activities of BRCA1.  In addition, the binding of 
proteins to the BRCT domain such as CtIP and their subsequent ubiquitination by 
BRCA1 suggests that efficient communication between the BRCT and RING domains is 
also critical for BRCA1 function.  Interestingly, it was found that a BRCA1 internal 
deletion mutant containing the RING and BRCT domains fused together was sufficient to 
target BRCA1 to DNA damage induced foci (Au and Henderson 2005).  This finding 
leaves much speculation to the role of the intervening region of BRCA1 in tumor 
suppression.  However, it has been suggested that the central region of BRCA1 might 
serve as a scaffold for proteins involved the DNA damage response as well as have a role 
in direct DNA binding (Mark et al. 2005) (Paull et al. 2001). 
    
The SQ cluster is the region of specific serine residues spanning amino acids 1241-1530 
of BRCA1 which are phosphorylated by the DNA-damage sensors ATM and ATR.  
ATM and ATR along with another DNA damage sensor, DNA-PKcs, are members of the 
phosphoinositide-3-kinase related protein kinase (PIKK) family and all three of these 
proteins are involved in DNA damage signaling (Falck et al. 2005).  These PIKK 
members are serine/threonine (S/T) kinases that phosphorylate substrates at these 
residues adjacent to a glutamine (Q) residue termed an S/TQ motif (Kim et al. 1999) 
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(O'Neill et al. 2000).  ATM is the principal kinase that phosphorylates BRCA1 in 
response to ionizing radiation (IR) (Cortez et al. 1999) (Gatei et al. 2000).  ATR may 
serve as a backup for ATM and is activated at stalled replication forks and in response to 
ultraviolet (UV) irradiation (Tibbetts et al. 2000).  The serine residues that are ATM/ATR 
targets identified within the BRCA1 SQ cluster are serines 1387, 1423, 1457, and 1524.  
Serine 1387 is uniquely phosphorylated by ATM in response to IR and serine 1457 is 
uniquely phosphorylated by ATR in response to UV irradiation whereas the other serines 
can be phosphorylated by both ATM and ATR depending on the type of damage (Gatei et 
al. 2001).  The known function of SQ cluster phosphorylation seems to be involved in 
cell-cycle regulation by BRCA1.  Serine 1387 phosphorylation is involved in the S-phase 
checkpoint whereas serine 1423/1524 phosphorylation is involved in G2/M checkpoint 
control (Fig. 2) (Xu et al. 2001) (Xu et al. 2002).   
 
 
 
 
 
 
 
 
 
 
 
 6
 
 
 
Figure 2.  Model of BRCA1 phosphorylation by ATM/ATR and the cellular 
consequences.  Serines 1387, 1423, 1457, and 1524 are located in the SQ cluster region 
of BRCA1.  Serine 1387 is of particular interest as it is specifically phosphorylated by 
ATM in response to IR.  Serine 1457 is phosphorylated by ATR in response to UV 
irradiation whereas serines 1423 and 1524 are overlapping ATM/ATR targets.  Serines 
1387 and 1423/1524 have been implicated in S and G2/M cell-cycle arrest, respectively.  
Outside the SQ cluster region is serine 988 which is indirectly phosphorylated by ATM 
via CHK-2 and is involved in modulating DSB repair.  It remains to be determined 
whether serine 1387 phosphorylation alone or in combination with the other SQ cluster 
serine residues is also involved in DSB repair. 
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Within the SQ cluster another serine, 1497, has been identified as a CDK-2 target 
(Ruffner et al. 1999).  Interestingly, outside the SQ cluster is serine 988 which is 
indirectly phosphorylated by ATM through CHK-2 (Lee et al. 2000).  In addition to cell-
cycle regulation, BRCA1 phosphorylation has also been shown to affect its localization 
and serine 988 phosphorylation has been specifically implicated in this process (Scully et 
al. 1997) (Okada and Ouchi 2003).  Most recently, another group has identified additional 
serine residues 1239 and 1330 and threonine 1720 of BRCA1 as DNA damage 
phosphorylation targets through large-scale proteomics (Matsuoka et al. 2007).  It 
remains to be determined the functions of these newly identified BRCA1 phosphorylation 
sites (Fig. 3).  
 
 
 
 
Figure 3.  Known BRCA1 serine phosphorylation sites, identified kinases, and 
functions.  Serines 1387, 1423, 1457, and 1524 are the SQ cluster ATM/ATR targets. 
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BRCA1 and DSB repair 
  
DSBs are the most lethal type of DNA damage experienced by the cell in response to 
DNA-damaging agents such as IR.  Therefore, the accurate repair of DSBs is critical for 
the maintenance of genome integrity, cell survival, and prevention of tumorigenicity 
(Kanaar et al. 1998).  DSBs can be repaired through two major mechanisms, homologous 
recombination repair (HRR) and non-homologous end-joining (NHEJ).  HRR is a high-
fidelity type of repair that occurs preferentially during the S and G2 cell-cycle phases 
when duplicated copies of chromosomes are present while error-prone NHEJ occurs 
throughout the cell cycle (Saleh-Gohari and Helleday 2004) (Rothkamm et al. 2003).  
Interestingly, BRCA1 may be involved in the decision by which mechanism the cell 
chooses to repair DSBs.  While both BRCA1 and BRCA2 have established roles in HRR 
through their association with the bacterial RecA homologue RAD51 recombinase, only 
BRCA1 has also been shown to be involved in the NHEJ pathway (Moynahan, Chiu et al. 
1999) (Moynahan, Pierce et al. 2001) (Scully et al. 1997) (Sharan et al. 1997) (Shinohara 
et al. 1992) (Zhong et al. 2002).  This seems to occur through the ATM/CHK-2 pathway 
in which CHK-2 phosphorylates BRCA1 on serine 988 (Lee, Collins et al. 2000).  It 
appears that this phosphorylation event skews the repair machinery toward HRR and 
prevention of error-prone NHEJ as well as promoting the fidelity of NHEJ (Zhang et al. 
2004) (Zhuang et al. 2006) (Wang et al. 2006).   
 
So how might ATM and BRCA1 come together at DSBs for BRCA1 phosphorylation 
and the initiation of BRCA1 mediated cellular events such as cell-cycle arrest and DSB 
repair?  The most recent literature suggests the following mechanism: following DNA 
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damage such as by IR the DNA-damage sensor ATM is activated.  ATM dimers 
autophosphorylate each other on serine 1981 leading to active monomers (Bakkenist and 
Kastan 2003).  Active ATM then phosphorylates the histone H2A variant H2AX on 
serine 139 (γ-H2AX) demarcating the site of the DSB (Rogakou et al. 1998).  This leads 
to MDC1 binding to γ-H2AX via its BRCT domain and recruitment of the Mre11-
RAD50-NBS1 (MRN) complex, ATM, and the ubiquitin ligases RNF8/Ubc13 to the site 
of the break (Stucki et al. 2005).  RNF8/Ubc13 then ubiquitinates H2AX leading to the 
recruitment of BRCA1/Abraxas(CCDC98)/RAP80 via the ubiquitin interacting motifs of 
RAP80 interacting with ubiquinated H2AX (Mailand et al. 2007) (Wang and Elledge 
2007).  BRCA1 can then be phosphorylated by ATM at the site of the DSB leading to 
downstream events such as cell-cycle arrest and DSB repair (Fig. 4). 
 
 
Figure 4.  Model of the recruitment of BRCA1 to the site of DSBs and activation by 
ATM.     
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It might be possible that differential phosphorylation events at this stage of the DNA 
damage response dictate a shift in BRCA1 BRCT domain binding partners.  This 
phosphorylation “code” might trigger direct conformational changes in BRCA1 leading 
to dissociation of CCDC98/RAP80 from the BRCT domain and interaction with either 
BACH1 or CtIP and/or indirectly influence alternative binding through differential cell-
cycle dependent phosphorylation of BACH1 and CtIP which occurs during S and G2, 
respectively (Yu and Chen 2004) (Yu, Chini et al. 2003).  Thus, in the unphosphorylated 
state CCDC98 may be the default BRCT domain binding partner for BRCA1 whereas 
serine 1387 phosphorylation might trigger binding with BACH1 since both of these are 
involved in S phase events whereas serine 1423/1524 phosphorylation might trigger CtIP 
binding which are both involved in G2/M cell-cycle arrest (Xu, O'Donnell et al. 2002) 
(Xu, Kim et al. 2001) (Yu, Fu et al. 2006) (Kumaraswamy and Shiekhattar 2007).  
Interestingly, it has been reported that BRCA1 also has a role in the recruitment of 
activated ATM to the site of DSBs (Kitagawa et al. 2004).  ATM is known to associate 
with BRCA1 as part of the BRCA1-asociated genome surveillance complex (BASC) 
suggesting another level of complexity might exist where BRCA1 has a role in the DNA 
damage response before and after ATM phosphorylation (Wang et al. 2000).          
 
In summary, much progress has been made over the past 15 years in discovering the 
functions of the BRCA1 protein.  Although many discoveries have been made regarding 
BRCA1 function, more fundamental questions remain to be answered.  Most notably, it 
remains to be determined why mutations in the BRCA1 gene are specifically linked to 
breast and ovarian cancers.  Also at hand is while 80% of hereditary cases of breast 
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cancer are associated with the BRCA1 and BRCA2 genes, this begs the question does a 
BRCA3 gene exist (Rosen, Fan et al. 2003)?  If so, will the BRCA3 protein also be 
involved in DSB repair like BRCA1 and BRCA2?  Until this discovery research will 
continue to focus on the known BRCA genes and is sure to bring about new findings.  
Most recently, a new protein, NBA1, has been found as part of the BRCA1 A complex 
and is involved in the DNA damage response (Wang et al. 2009).  There is certainly no 
doubt that ongoing research into BRCA1 function will lead to the discovery of new 
cellular partners and roles as we continue to unravel the mysteries of this truly complex 
and multifaceted protein.  
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Chapter 2:  Hypothesis and Specific Aims 
 
Hypothesis 
 
Most mutations in BRCA1 leading to breast and ovarian cancers have been found in the 
RING and BRCT domains (Couch and Weber 1996).  Given the importance of the 
BRCA1 BRCT domain in binding proteins involved in HRR such as RAP80, BACH1, 
and CtIP, it is likely that mutations in the BRCT domain that disrupt phospho-protein 
binding would also impact HRR.  Previous studies have shown that the naturally 
occurring BRCA1 BRCT mutation M1775R which disrupts BRCA1 interaction with CtIP 
results in decreased cell survival in response to IR when re-introduced into the BRCA1 
defective human breast carcinoma cell line HCC1937 which is hypersensitive to IR (Yu 
et al. 1998) (Scully et al. 1999).  HCC1937 cells contain a mutation in the BRCA1 gene, 
5382InsC, leading to termination at codon 1829 and deletion of the C’ terminal 33 amino 
acids of the BRCA1 protein (Tomlinson et al. 1998).  This mutation corresponds to 
deletion of the second BRCT repeat of the BRCA1 BRCT domain.   
 
Crystallography studies of phospho-peptides representing BACH1 and CtIP binding to 
the BRCA1 BRCT domain as well as mutagenesis binding studies of sites in the BACH1 
peptide have been carried out by several groups (Clapperton et al. 2004) (Williams et al. 
2004) (Varma et al. 2005).  These studies revealed that the phospho-serine moiety of the 
pSer-X-X-Phe motif of the BACH1 peptide formed significant interactions with several 
residues within the phospho-serine binding pocket of the BRCA1 BRCT domain.  These 
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studies also demonstrated how the M1775R mutation would sterically clash with the 
phenylalanine ring of the pSer-X-X-Phe motif to disrupt phospho-protein binding (Fig.  
5). 
 
 
 
Figure 5.  Representation of the BRCA1 BRCT domain interaction with a phospho-
peptide representing BACH1.  The BRCA1 BRCT domain binds phospho-proteins 
containing the phospho-serine-X-X-phenylalanine (pSer-X-X-Phe) motif, X representing 
any amino acid.  The phosphate moiety of the phosphorylated serine forms hydrogen 
bonds with several residues including lysine 1702 of BRCA1 in the binding pocket of the 
first (N’ terminal) BRCT repeat.  The phenylalanine ring of the motif forms van der 
Waals interactions with several residues including methionine 1775 of BRCA1 in a 
hydrophobic groove located between the two BRCT repeats. 
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Of particular interest was lysine 1702 (K1702) which interacts directly with the 
phosphate moiety of the phosphorylated serine using the positively charged amino 
portion of its R group.  The BRCA1 BRCT domain mutated at position 1702 to 
methionine (K1702M) was found to result in a substantial reduction in BACH1 peptide 
binding (Clapperton, Manke et al. 2004) (Williams, Lee et al. 2004).  Disruption of this 
critical interaction would also be expected to disrupt the interaction of BRCA1 with full-
length phospho-proteins involved in HRR.  This would allow study of how BRCA1 
BRCT mutants such as M1775R that disrupt BRCA1 interactions with phospho-proteins 
affect DSB repair and specifically HRR.  The results of these studies could shed light on 
how these BRCA1 BRCT mutations would contribute to the onset of breast and ovarian 
cancers through altered DSB repair.              
 
There is also evidence that BRCA1 phosphorylation affects DSB repair.  BRCA1 
phosphorylation at serine 988 by CHK-2 has been implicated in DSB repair by promoting 
HRR and inhibiting NHEJ as well as promoting the fidelity of NHEJ (Zhang, Willers et 
al. 2004) (Wang, Chou et al. 2006) (Zhuang, Zhang et al. 2006).  Serine 988 
phosphorylation has also been shown to affect BRCA1 sub-cellular localization in 
response to DNA damage (Okada and Ouchi 2003).  However, it remains to be 
determined whether serine 1387 phosphorylation alone or in combination with the other 
BRCA1 SQ cluster serine ATM/ATR phosphorylation sites also affects DSB repair and 
BRCA1 localization.  Serine 1387 is of particular interest as it is uniquely phosphorylated 
by ATM in response to IR and serine 1387 phosphorylation has been implicated in the S-
phase checkpoint (Gatei, Zhou et al. 2001) (Xu, O'Donnell et al. 2002).  It is therefore 
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possible that serine 1387 phosphorylation might also be involved in DSB repair and 
BRCA1 sub-cellular localization in response to IR. 
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Specific Aims 
 
1.  Determine the role of the BRCA1 BRCT domain in DSB repair. 
 
A.  Determine whether mutations in the BRCT domain that affect BRCA1     
      binding to phospho-proteins also affect HRR. 
 
B. Determine the molecular mechanisms that might account for altered DSB  
      repair. 
 
2.  Determine the role of BRCA1 SQ cluster serine phosphorylation in DSB repair. 
 
A. Determine the effect of BRCA1 serine 1387 phosphorylation on radiosurvival. 
 
B.  Determine whether serine 1387 phosphorylation affects the cytoplasmic- 
      nuclear shuttling of BRCA1.  
 
C.  Determine the effect of serine 1387 phosphorylation in combination with the  
      other SQ cluster ATM/ATR phosphorylation sites on HRR. 
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Chapter 3 
 
A K1702M mutation in the BRCT active site of BRCA1 results in hyper-
recombination 
 
Introduction  
 
It is currently believed that mutations within the N’ terminal RING and C’ terminal 
BRCT domains result in a loss of the tumor suppressor functions of BRCA1 leading to 
genomic instability and ultimately the onset of breast and ovarian cancers (Couch and 
Weber 1996) (Shen and Vadgama 1999).  Because BRCA1 is involved in DSB repair and 
the BRCA1 BRCT domain binds several factors important in this process, we sought to 
determine the importance of the BRCT domain of BRCA1 in DSB repair (Moynahan, 
Chiu et al. 1999) (Zhang, Willers et al. 2004) (Sartori, Lukas et al. 2007) (Litman, Peng 
et al. 2005) (Yan, Kim et al. 2007).  The crystal structure of the BRCA1 BRCT domain 
interacting with a phospho-peptide representing BACH1 and functional mutagenesis 
revealed that lysine 1702 (K1702) was important in the interaction of phospho-proteins 
with the BRCT domain (Clapperton, Manke et al. 2004) (Williams, Lee et al. 2004).  We 
therefore sought to determine how mutating lysine 1702 in the active site of the BRCA1 
BRCT domain to methionine (K1702M) would affect DSB repair and specifically HRR, 
focusing on the interaction of BRCA1 with CtIP. 
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In the present study we demonstrate that the BRCA1 K1702M mutant is hyper-
recombinogenic, leads to S/G2 phase cell-cycle arrest, and radiosensitizes BRCA1-
defective HCC1937 human breast carcinoma cells.  Interestingly, we found that the 
K1702M mutant can also result in reduced levels of HRR when over-expressed in U87 
human glioma cells which express endogenous, wild-type BRCA1.  We also show that 
this mutant is defective in CtIP binding and that an additional I26A mutation in the N’ 
terminal RING domain which disrupts the ubiquitin ligase activity of BRCA1 silences the 
hyper-recombinogenic phenotype of the K1702M mutant suggesting that BRCA1 
ubiquitin ligase activity has a dominate role over BRCT domain mediated phospho-
protein interactions in the HRR activity of BRCA1.  We further show that BRCA1 
K1702M enhances the ubiquitination of BRCA1 and associated proteins suggesting that 
ubiquitination has a major role in HRR.  Altogether, these findings provide the first 
evidence that mutations within the BRCT domain of BRCA1 may lead to genomic 
instability due to enhanced BRCA1 function in which increased levels of HRR lead to 
aberrant homologous recombination while mutations in the RING domain that disrupt the 
ubiquitin ligase activity of BRCA1 are dominant over those in the BRCT domain and 
abolish the HRR activity of BRCA1 in response to DNA damage. 
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Experimental Results  
 
Generation of adenovirus expressing BRCA1.  To efficiently express full-length 
BRCA1 in HCC1937 cells which are homozygous for the BRCA1 5382insC mutation, we 
generated helper-dependent adenoviral (HD-Ad) vectors co-expressing BRCA1 as well 
as a LacZ reporter (Fig. 6-A) (Tomlinson, Chen et al. 1998) (Palmer and Ng 2003).  To 
test the infectivity of HCC1937 cells with these vectors, we performed β-galactosidase 
(LacZ) staining of infected cells.  Nearly 100% of HCC1937 cells were infected using 
these vectors as demonstrated by the high levels of staining of infected cells compared to 
uninfected cells (Fig. 6-B).  To confirm that these vectors express full-length BRCA1 in 
HCC1937 cells, we performed western blotting and found expression of the full-length 
BRCA1 protein migrated above the endogenous, truncated BRCA1 protein bands (Fig. 6-
C).  The relative levels of virus-expressed BRCA1 and endogenous, truncated BRCA1 
was relatively similar (2.6-fold) which is critical since too much expression could 
possibly offset any beneficial effects.  These results demonstrate that the HD-Ad vectors 
infect HCC1937 cells and express full-length BRCA1 at physiological levels.  
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Figure 6.  BRCA1 helper-dependent adenoviral (HD-Ad) vectors infect HCC1937 
cells and express full-length BRCA1.  (A) Cartoon representation and amplification 
scheme of the HD-Ad vector co-expressing BRCA1 with a combined influenza 
hemagglutinin (HA) and triple FLAG (3XFLAG) epitope tag at the N’ terminus of 
BRCA1 and a β-galactosidase (LacZ) reporter (ITR – inverted terminal repeat).  
Following transfection of PmeI linearized HD-Ad DNA into HEK293-116C cells which 
express the Cre recombinase, the HD-Ad is amplified and packaged following infection 
with a helper virus (HV) containing loxP sites flanking the HV packaging signal.  This 
system allows the HV to supply the HD-Ad with viral proteins in trans but only is HD-
Ad is packaged following Cre-mediated excision of the HV packaging signal.  After the 
initial HD-Ad transfection/HV infection, serial co-infections of both viruses generate an 
HD-Ad crude stock with minimal HV contamination.  (B) LacZ staining for β-
galactosidase expression 48 hrs post-infection with HD-Ad vector control, wild-type 
BRCA1 (BRCA1wt), or uninfected HCC1937 cells.  (C)  Lysates from HCC1937 cells 
infected as described in B were probed with anti-FLAG (HD-Ad BRCA1) and anti-
BRCA1 (HD-Ad BRCA1 + endogenous 5382insC BRCA1) antibodies.  Arrows 
represent protein bands related to endogenous 5382insC BRCA1.  
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Wild-type BRCA1 increases homologous recombination repair (HRR) in HCC1937 
cells.  Having demonstrated full-length BRCA1 expression in HCC1937 cells using the 
HD-Ad vector system, we next determined the effect of wild-type BRCA1 expression on 
HRR in these cells.  To detect HRR events by green fluorescent protein (GFP) expression 
in HCC1937 cells, we stably transfected these cells with the DR-GFP repair substrate 
which has been described previously (Pierce et al. 1999).  Briefly, the repair substrate 
contains two mutant GFP genes separated by 3.7 kb.  One gene has been mutated to 
contain a recognition site for the rare-cutting yeast I-SceI endonuclease and the other 
gene is an internal fragment of the GFP gene spanning the site of the mutation in the 
other gene.  Cleavage within the recognition site by ectopic expression of I-SceI from 
adenovirus generates a single DSB in the repair substrate which can be repaired using the 
internal fragment as a homologous template resulting in GFP positive cells (Anglana and 
Bacchetti 1999).   
 
Using this HCC1937/DR-GFP cell system, we found that infection with the wild-type 
BRCA1 HD-Ad resulted in > 3-fold GFP positive cells compared with vector control 
infected cells and vector control infected cells had levels of repair similar to those of 
uninfected cells (Fig. 7-A).  These results were statistically significant when wild-type 
BRCA1 and vector control infected cells were compared (P = 0.0017) (Fig. 7-B).  These 
results demonstrate that we can rescue the repair defect and conduct HRR assays in 
HCC1937 cells by GFP expression using our BRCA1-expressing viral vector system.        
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Figure 7.  Rescue of HRR in HCC1937 cells with expression of wild-type BRCA1 
from virus.  (A) HCC1937 cells with an integrated DR-GFP repair substrate express 
green fluorescent protein (GFP) following a homologous recombination repair (HRR) 
event after I-SceI cleavage within the repair substrate.  HCC1937/DR-GFP cells were 
serum starved and infected with HD-Ad vectors expressing vector control or wild-type 
BRCA1 or left uninfected.  48 hrs post HD-Ad infection, cells were infected with an 
adenovirus expressing the I-SceI endonuclease (Ad-SceI) and analyzed 48 hrs post Ad-
SceI infection for HRR/GFP events by fluorescence-activated cell sorting (FACS).  (B) 
Quantification of results in A.  Error bars represent the standard error of the mean (SEM) 
of triplicate determinations (** P < 0.01 when wild-type BRCA1 and vector control 
infected cells were compared).   
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BRCA1 K1702M disrupts binding with CtIP.  To investigate how the K1702M 
mutation would affect binding of full-length proteins to the BRCA1 BRCT domain we 
conducted co-immunoprecipitation experiments in HEK293T cells with BRCA1 and a 
protein known to bind to the BRCA1 BRCT domain, CtIP (Yu and Chen 2004).  
Experiments conducted with wild-type BRCA1 demonstrated that CtIP would co-
immunoprecipitate with BRCA1 when co-expressed by plasmid transfection (Fig. 8-A).  
Interestingly, we also observed a stabilization effect of both BRCA1 and CtIP when 
expressed together demonstrating a significant interaction among these proteins.  When 
the binding of CtIP to wild-type BRCA1 was compared with BRCA1 K1702M, we found 
that the K1702M mutant resulted in ~ 10-fold less binding of CtIP (Fig. 8-B).  These 
results demonstrate that the BRCA1 K1702M mutant disrupts binding with full-length 
BRCA1 BRCT-interacting proteins, and specifically CtIP, in a manner that could also 
influence DSB repair. 
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Figure 8.  BRCA1 K1702M prevents binding to CtIP compared to wild-type 
BRCA1.  (A) HEK293T cells were transfected with plasmids expressing FLAG-BRCA1 
wild-type, Myc-CtIP, or empty vector (pcDNA3) where indicated.  48 hrs post-
transfection total cell extracts were immunoprecipitated with FLAG beads and samples 
were probed with either FLAG or Myc antibody.  DNA-PKcs served as a loading control.  
(B) FLAG-BRCA1 wild-type or K1702M mutant was co-transfected with Myc-CtIP as in 
A.    
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BRCA1 K1702M results in hyper-recombination in HCC1937 cells.  Having 
established our GFP-based HRR assay in the HCC1937 cells using the wild-type BRCA1 
virus and demonstrated the impaired binding capacity of the K1702M mutant, we next 
tested the effect of BRCA1 K1702M on HRR.  Because the BRCA1 BRCT domain 
interacts with proteins involved in HRR, we expected to observe decreased HRR with 
this BRCT binding mutant compared to wild-type BRCA1.  Surprisingly, we found that 
BRCA1 K1702M increased HRR > 3-fold compared to wild-type BRCA1 and that this 
result was consistent across three 2-fold dilutions of virus (Fig. 9-A).  These results were 
statistically significant when wild-type BRCA1 infected cells were compared with vector 
control and K1702M mutant infected cells (P = 0.0028 and 0.0004, respectively) and 
when vector control and K1702M mutant infected cells were compared (P = 0.0001).  
Interestingly, the hyper-recombinogenic phenotype of BRCA1 K1702M did not increase 
the survival of infected HCC1937 cells in response to ionizing radiation while BRCA1 
wild-type infected cells rescued HCC1937 cell survival above vector control infected 
cells (Fig. 9-B).  These results were statistically significant when vector control infected 
cells were compared with wild-type BRCA1 and K1702M mutant infected cells (P = 
0.0022 and 0.0047, respectively).  Similar levels of protein expression and infection 
efficiencies for BRCA1 wild-type and K1702M mutant infected HCC1937 cells were 
confirmed by western blotting and LacZ staining, respectively (Fig. 9-C).  Interestingly, 
LacZ staining revealed that BRCA1 K1702M infected cells appeared to have a different 
morphology appearing more rounded up and less dense compared to BRCA1 wild-type 
and vector control infected cells.  
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Figure 9.  Expression of BRCA1 K1702M in HCC1937 cells results in hyper-
recombination and increased radiosensitivity.  HCC1937/DR-GFP cells were infected 
with HD-Ad vectors expressing vector control, BRCA1 wild-type or K1702M mutant, or 
left uninfected.  (A) Cells were serum starved and 48 hrs post HD-Ad infection (at either 
a single dose of virus in triplicate or at decreasing doses in single determinations) cells 
were infected with Ad-SceI and analyzed 72 hrs post Ad-SceI infection for HRR/GFP 
events by FACS.  Error bars represent the SEM of triplicate determinations (** P < 0.01 
and *** P < 0.001 when wild-type BRCA1 was compared with vector control and 
K1702M mutant, respectively.  *** P < 0.001 when vector control was compared with 
K1702M mutant).  (B) 72 hrs post HD-Ad infection cells were irradiated with doses of 
either 4 or 8 Gy or left unirradiated.  7 days post-irradiation, cells were counted by FACS 
after the addition of Trypan Blue.  Error bars represent the SEM of triplicate 
determinations (** P < 0.01 when vector control was compared with BRCA1 wild-type 
and K1702M mutant at 8 Gy, respectively). (C) Western blotting with FLAG antibody 
for BRCA1 expression and LacZ staining of infected cells.  DNA-PKcs served as a 
loading control. 
 
 
BRCA1 is important for HRR in U87 glioma cells.  To determine what effect BRCA1 
K1702M might have on HRR in non-breast cancer cell lines, and specifically in U87 
human glioma cells which express wild-type BRCA1, we first determined the importance 
of endogenous BRCA1 on HRR in these cells using RNA interference methods.  
Treatment of two U87/DR-GFP cell clones expressing BRCA1 shRNA under 
doxycycline (DOX)-inducible control for six days resulted in the reduction of 
endogenous BRCA1 levels by at least 40% compared to untreated cells (Fig. 10-A).  
When these cells were assessed for HRR/GFP events by GFP flow cytometry, a 40-60% 
reduction in the number of GFP positive cells was observed (Fig. 10-B).  Thus, the 
decrease in the number of GFP-expressing cells in response to DOX suggests that 
reducing BRCA1 protein levels impairs HRR and that BRCA1 is important for HRR in 
U87 cells. 
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Figure 10.  Knock-down of BRCA1 expression in U87 cells reduces HRR.  Two 
U87/DR-GFP cell clones transduced with a doxycycline (DOX)-inducible lentiviral 
vector expressing a BRCA1-directed shRNA were treated with 5µg/mL DOX for six 
days or left untreated.  (A) Western blotting of BRCA1 levels.  (B) Cells were infected 
with Ad-SceI 72 hrs after DOX treatment and analyzed for HRR/GFP events by FACS 72 
hrs post-infection with continued DOX treatment.  Error bars represent the SEM of 
triplicate determinations. 
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BRCA1 K1702M has a dominant-negative effect on HRR in U87 cells.  Having 
established the importance of BRCA1 on HRR in U87 cells using shRNA, we next 
determined the effect of BRCA1 K1702M expression on HRR in U87 cells using the HD-
Ad vectors.  Surprisingly, we found that the K1702M mutant reduced the levels of HRR 
of U87 cells 3-fold compared to wild-type BRCA1 and vector control infected cells (Fig. 
11-A).  Interestingly, over-expressing wild-type BRCA1 did not increase HRR levels 
above vector control levels although the HD-Ad vectors expressed BRCA1 at ~20-fold 
greater levels compared to endogenous BRCA1 (Fig. 11-B).  These results suggest that 
BRCA1 K1702M has a dominant-negative effect in cells endogenously expressing wild-
type BRCA1.   
 
 
 
Figure 11.  Over-expression of BRCA1 K1702M reduces HRR in U87 cells.  (A) 
U87/DR-GFP cells were infected with HD-Ad vectors expressing vector control, BRCA1 
wild-type or K1702M mutant.  48 hrs post HD-Ad infection cells were infected with Ad-
SceI and analyzed 72 hrs post Ad-SceI infection for HRR/GFP events by FACS.  Error 
bars represent the SEM of triplicate determinations.  (B) Western blotting of BRCA1 
levels in uninfected and cells infected with wild-type BRCA1 HD-Ad. 
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Enhanced homologous recombination repair correlates with increased radiation-
induced RAD51 foci formation and nuclear staining of BRCA1 K1702M infected 
HCC1937 cells.  To verify the results of the GFP-based HRR assay, we examined the 
homologous recombination specific protein RAD51 in irradiated HCC1937 cells using 
immunocytochemistry.  In support of the GFP results, BRCA1 K1702M infected cells 
exposed to 4 Gy irradiation displayed much higher levels of RAD51 than wild-type 
BRCA1 infected cells while only a modest increase was observed with wild-type BRCA1 
irradiated cells compared to vector control (Figs. 12-A,B).  These results were 
statistically significant when wild-type BRCA1 and K1702M mutant irradiated cells were 
compared (P = 0.0053).  Interestingly, RAD51 levels were also much higher in 
unirradiated BRCA1 K1702M infected cells compared to wild-type BRCA1 and vector 
control infected cells demonstrating that the hyper-recombinogenic phenotype is present 
in the absence of irradiation in a constitutive manner.  These results were statistically 
significant when wild-type BRCA1 and K1702M mutant unirradiated cells were 
compared (P = 0.0007).  Western blot analysis of RAD51 in BRCA1 K1702M infected 
cells showed an increase in RAD51 dimerization not present in wild-type BRCA1 and 
vector control infected cells (Fig. 12-C).  This result is in line with the finding that the 
active unit of RAD51 in the filament may be a dimer (Conway et al. 2004).  Altogether, 
these results suggest that BRCA1 K1702M infected cells are somehow primed to undergo 
more homologous recombination, whether exposed to irradiation or if DSBs are created 
artificially using a restriction endonuclease in the HRR-GFP repair cassette.  
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Figure 12.  BRCA1 K1702M enhances RAD51 immunocytochemical staining and 
dimerization in HCC1937 cells.  HCC1937/DR-GFP cells were infected with HD-Ad 
vectors expressing vector control, wild-type BRCA1, or K1702M mutant.  48 hrs post 
HD-Ad infection, cells were  exposed to 4 Gy irradiation or left unirradiated and stained 
for RAD51 protein 8 hrs after irradiation.  (A) RAD51 staining.  (B) Quantification of 
results in A.  Error bars represent the SEM of 10 random fields analyzed from three 
independent experiments with at least 100 cells per sample (*** P < 0.01 and ** P < 
0.001 when BRCA1 wild-type and K1702M mutant unirradiated and irradiated cells were 
compared, respectively).  (C) Western blot of RAD51 levels in unirradiated cells 48 hrs 
post-infection.  
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Expression of BRCA1 K1702M in HCC1937 cells results in increased S and G2 
phase cell-cycle arrest.  To explain the underlying cause of the hyper-recombinogenic 
phenotype observed with BRCA1 K1702M, we next determined whether this mutant 
might have an effect on the cell-cycle distribution of HCC1937 cells in a manner that 
might enhance HRR.  We found that infection with BRCA1 K1702M resulted in > 2-fold 
increases in the S and G2 phases of the cell cycle with a corresponding decrease in the 
G1 phase over a 48 hr time period while there were no differences between vector control 
and wild-type BRCA1 infected cells (Fig. 13).  These results support our HRR/GFP and 
RAD51 data and suggest that at the time the I-SceI break is induced in the repair cassette 
or the cells are exposed to irradiation after BRCA1 K1702M infection (48 hrs), the 
HCC1937 cells are primed to undergo more homologous recombination which is 
enhanced during the S and G2 phases of the cell-cycle when duplicated copies of 
chromosomes and repair factors are available for HRR (Saleh-Gohari and Helleday 2004) 
(Rothkamm, Kruger et al. 2003).       
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Figure 13.  BRCA1 K1702M arrests HCC1937 cells in S and G2.  HCC1937/DR-GFP 
cells were serum starved and infected with HD-Ad vectors expressing vector control, 
wild-type BRCA1, or K1702M mutant.  Cells were collected at 8, 16, 24, and 48 hrs after 
HD-Ad infection and cell-cycle distribution was analyzed by flow cytometry after 
propidium iodide staining. 
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BRCA1 K1702M enhances ubiquitination of BRCA1 and associated proteins and 
ubiquitination correlates with homologous recombination repair.  Because BRCA1 is 
known to ubiquitinate CtIP, we tested what effect decreased CtIP binding might have on 
BRCA1 ubiquitination (Yu, Fu et al. 2006).  Surprisingly, we found that BRCA1 
K1702M enhanced BRCA1 autoubiquitination and ubiquitination of BRCA1 associated 
proteins when immunoprecipiated BRCA1 from HEK293T cells co-transfected with 
BRCA1 and ubiquitin over-expression plasmids was probed for ubiquitin (Fig. 14-A).  
As expected, the BRCA1 I26A ubiquitin ligase mutant, which is known not to interact 
with the E2 ubiquitin conjugase but still bind BARD1, showed decreased ubiquitination 
of BRCA1 and associated proteins while binding CtIP similar to wild-type BRCA1 levels 
(Figs. 14-A, B) (Brzovic et al. 2003).  However, when we examined a BRCA1 
I26A/K1702M double mutant, we found that decreased ubiquitination silenced the hyper-
recombinogenic phenotype of the single BRCA1 K1702M mutant while the double 
mutant displayed similar binding to CtIP as the single mutant (Figs. 14-A, B, C).  These 
results imply that BRCA1 ubiquitination mediated by the RING domain is important for 
HRR and has a dominant role over HRR mediated by BRCT domain phospho-protein 
interactions suggesting that these two domains must communicate with each other for 
efficient HRR.   
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Figure 14.  BRCA1 K1702M enhances the ubiquitination of BRCA1 and associated 
proteins and ubiquitination correlates with HRR.  (A) HEK293T cells were co-
transfected with FLAG-BRCA1 and Myc-ubiquitin over-expression plasmids and 
immunoprecipitated FLAG material was probed with Myc antibody to ubiquitin (Ub) 48 
hrs post-transfection.  (B) The indicated FLAG-BRCA1 plasmids were co-transfected 
with Myc-CtIP plasmid as in 8-B.  (C) HCC1937/DR-GFP cells were infected with HD-
Ad vectors expressing vector control, BRCA1 wild-type, K1702M mutant, or 
I26A/K1702M double mutant, or left uninfected and analyzed for HRR/GFP events by 
FACS as in 9-A.  Error bars represent the SEM of triplicate determinations. 
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Chapter Summary  
 
The BRCA1 tumor suppressor protein has many known roles in the cell including roles in 
both the HRR and non-homologous end-joining pathways of DSB repair (Moynahan, 
Chiu et al. 1999) (Zhong, Chen et al. 2002).  However, it remains to be determined the 
exact role of the BRCA1 BRCT domain in the DSB repair process.  In this report, we 
examined a K1702M mutation in the BRCT domain of BRCA1 which was shown to 
disrupt binding with a phospho-peptide representing BACH1 to the BRCT domain 
(Clapperton, Manke et al. 2004) (Williams, Lee et al. 2004).  When we examined what 
effect this mutation might have on HRR we were surprised to find that it stimulated the 
HRR pathway.  This stimulation coincided with S and G2 phase cell-cycle arrest.  We 
were also surprised to find that the increase in HRR resulted in decreased radiosurvival.  
That a mutation that disrupts the binding of BRCA1 with other proteins would stimulate 
HRR at the expense of cell survival suggests a novel mechanism whereby BRCA1 BRCT 
mutations might lead to breast and ovarian cancers through enhanced HRR which is 
aberrant rather than through a loss of DSB repair function. 
  
The BRCA1 BRCT domain is known to bind to three phospho-proteins in three mutually 
exclusive complexes with CtIP, BACH1, and RAP80 (Yu and Chen 2004) (Cantor, Bell 
et al. 2001) (Wang, Matsuoka et al. 2007).  Additionally, all three of these proteins have 
been show to be directly involved in HRR (Sartori, Lukas et al. 2007) (Litman, Peng et 
al. 2005) (Yan, Kim et al. 2007).  RAP80 has been show to localize BRCA1 to the site of 
DSBs through its ubiquitin interacting motifs which interact with ubiquinated H2AX 
while the BACH1 helicase has been found to be important in S-phase progression 
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(Sobhian, Shao et al. 2007) (Kumaraswamy and Shiekhattar 2007).  However, we chose 
to look at CtIP in our study which is uniquely ubiquitinated by BRCA1 and is involved in 
G2/M cell-cycle arrest (Yu, Fu et al. 2006).  In addition, CtIP has also been reported to 
act as an adaptor to facilitate the binding of BRCA1 to the MRN complex, a complex 
which is directly involved in the DSB repair process (Chen et al. 2008).  As expected, we 
found that BRCA1 K1702M bound much less efficiently to CtIP than wild-type BRCA1 
demonstrating that this mutant could serve as a model for how impaired BRCA1 BRCT 
binding might impact DSB repair.   
 
The HRR/GFP results gave > 3-fold increases in HRR with the K1702M mutant 
compared to wild-type BRCA1 in HCC1937 cells.  However, we observed a 3-fold 
decrease in HRR when BRCA1 K1702M was over-expressed in U87 glioma cells 
suggesting that the hyper-recombinogenic phenotype is either specifically associated with 
breast cancer cells or does not manifest itself in cells endogenously expressing wild-type 
BRCA1.  We further verified the HRR/GFP results in HCC1937 cells by looking at the 
HRR-specific protein RAD51 in irradiated cells.  Although we observed increases in 
RAD51 foci and nuclear staining in response to irradiation, the K1702M mutant showed 
dramatic increases in RAD51 levels compared to wild-type BRCA1 with or without 
irradiation.  That the RAD51 levels were increased without irradiation suggests the 
BRCA1 BRCT mutant is a constitutively active molecule in terms of HRR and is 
promoting homologous recombination in an uncontrolled manner.   
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We were also surprised to find that BRCA1 K1702M increased the ubiquitination of 
BRCA1 and associated proteins in immunoprecipitation experiments with ubiquitin.  
Interestingly, it has been demonstrated that autoubiquitination enhances BRCA1 
ubiquitin ligase activity (Mallery, Vandenberg et al. 2002).  Coupled with our HRR 
findings, this again suggests that BRCA1 K1702M is enhanced in its activity compared to 
wild-type BRCA1 protein.  We also found that the level of ubiquitination correlated with 
HRR.  When we created an additional I26A mutation to disrupt the ubiquitin ligase 
activity of BRCA1 (I26A/K1702M), we found that it silenced the hyper-recombinogenic 
phenotype while still maintaining the same impaired binding capacity of CtIP as the 
single K1702M mutant.  This result suggests that ubiquitination is important for HRR and 
that the RING domain has a dominate role over BRCT domain mediated phospho-protein 
interactions in the HRR activity of BRCA1.  It also suggests that there must be a 
coordinated communication between these two domains for efficient HRR.   
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Chapter Methods 
 
Cell culture.  All cells were cultured at 37ºC, 5% CO2.  HCC1937 cells were cultured in 
RPMI 1640 media (Cellgro), HEK293-116C and HEK293T cells were cultured in 
DMEM (Gibco), and U87 cells were cultured in MEM Alpha media (Gibco), all 
supplemented with 10% FBS (Gibco).    
 
Western blotting.  All cell lysates were harvested in RIPA buffer (10 mM Tris, 1% 
TritonX-100, 0.1% SDS, 1 mM EDTA, 0.1% Na deoxycholate, 0.5 mM EGTA, and 140 
mM NaCl) with inhibitors (protease and phosphatase (Sigma cocktails) at 1:100 dilution 
and 1 mM PMSF) and separated by SDS-PAGE for immunoblotting.  BRCA1 protein 
was probed with anti-FLAG (M2, Sigma) and anti-BRCA1 (Ab-1, Oncogene) antibodies.  
CtIP and ubiquitin were probed with anti-Myc antibody (9B11, Cell Signaling), RAD51 
with anti-RAD51 antibody (Ab-1, Calbiochem), and DNA-PKcs with anti-DNA-PKcs 
antibody (Biosource, 4F10C5).  All antibodies were used at a 1:1000 dilution except anti-
BRCA1 (Ab-1, Oncogene) which was used at 1:50.  Secondary antibodies used were 
either anti-mouse 680 Alexa (Molecular Probes) or anti-rabbit IRDYE 800 (Rockland 
Immunochemicals), both at a 1:3000 dilution.  Protein bands were visualized and 
quantified using the Odyssey Infrared Imaging System (Li-Cor Biosciences).   
 
Generation of HD-Ad vectors.  QuikChange site-directed mutagenesis (Stratagene) was 
used to create the K1702M mutation from wild-type (wt) BRCA1 sequence using primers 
GTGAACGGACACTGATGTATTTTCTAGGAATTG and 
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CAATTCCTAGAAAATACATCAGTGTCCGTTCAC.  The I26A mutation was created 
using primers CTTAGAGTGTCCCGCCTGTCTGGAGTTG and 
CAACTCCAGACAGGCGGGACACTCTAAG.  Plasmids pcDNA3(BssHII)-HA-
3XFLAG-BRCA1 wt, K1702M, I26A, and I26A/K1702M were digested with BssHII and 
the HA-3XFLAG-BRCA1 fragments ligated into the AscI site of the helper-dependent 
adenovirus (HD-Ad) p∆28E4LacZ (kindly provided by Philip Ng) (Palmer and Ng 2003).  
The p∆28E4LacZ-HA-3XFLAG-BRCA1 plasmids co-expressing HA-3XFLAG-BRCA1 
and a β-galactosidase (LacZ) reporter were then digested with PmeI to release the linear 
viral DNA.  The viral DNA was rescued and amplified by transfecting HEK293-116C 
cells using Superfect (Qiagen) and following the protocol described previously to obtain 
crude virus stocks (Palmer and Ng 2003).      
 
HRR/GFP DSB repair assay.  The DR-GFP repair substrate has been described 
previously (Pierce, Johnson et al. 1999).  Clonal HCC1937 cells stably transfected with 
DR-GFP were selected in puromycin.  HCC1937/DR-GFP cells at ~90% confluency 
were serum-starved by washing cells 4X 5 min with serum free media and infected 48 hrs 
later with HD-Ad vectors.  At 48 hrs post HD-Ad infection, cells were infected with an 
adenovirus expressing the I-SceI endonuclease (Ad-SceI) and analyzed at either 48 or 72 
hrs post Ad-SceI infection for HRR/GFP events by FACS as previously described 
(Golding et al. 2007).  U87/DR-GFP cells were transduced with a doxycycline (DOX)-
inducible lentiviral vector system expressing a BRCA1-directed shRNA to the sequence 
5’-GAAAGTACGAGATTTAGTC-3’ as described and two clonal cell lines were 
established (Wiznerowicz and Trono 2003) (Fabbro et al. 2004).  Cells were treated with 
 43
5µg/mL DOX for three days, infected with Ad-SceI with continued DOX treatment, and 
analyzed for HRR/GFP events by FACS 72 hrs post-infection as described (Golding, 
Rosenberg et al. 2007).  Unpaired two-tailed t tests were performed on data sets using 
GraphPad Prism 3.0 (GraphPad Software, Inc.). 
 
Co-immunoprecipitation assays.  HEK293T cells were transiently co-transfected with 
pcDNA3(BssHII)-HA-3XFLAG-BRCA1 constructs and plasmids pcDNA3-Myc-CtIP 
(kindly provided by Joseph Nevins) or pCMV-Myc-ubiquitin (kindly provided by 
Natsuko Chiba) using polyethylenimine (Polysciences, Inc.) (Starita et al. 2005) (Meloni 
et al. 1999).  Cells were harvested in RIPA buffer 48 hrs post-transfection and BRCA1 
was immunoprecipitated overnight using red anti-FLAG M2 affinity gel (Sigma) in 0.5X 
RIPA/PBS with inhibitors (protease and phosphatase (Sigma cocktails) at 1:100 dilution 
and 1 mM PMSF) in a final volume of 5 mL and washed 3X with 1X PBS with 
inhibitors.     
 
Immunocytochemistry.  HCC1937/DR-GFP cells were seeded onto 4-well chamber 
slides and infected with HD-Ad vectors.  48 hrs post HD-Ad infection cells were 
irradiated with 4 Gy or left unirradiated using a Gammacell 40 Exactor (MDS Nordion).  
8 hrs after irradiation cells were fixed with 3% paraformaldehyde, permeablized with 
0.5% TritonX-100, stained using anti-RAD51 antibody (Ab-1, Calbiochem) at 1:500 
dilution and Alexa Fluor 488 goat anti-rabbit IgG antibody (Molecular Probes) at 1:500 
dilution, and counterstained using Vectashield Mounting Media with DAPI (1.5 µg/mL).  
Stained cells were visualized using the Applied Imaging Ariol (Genetix) at 40X 
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magnification and images were quantified using CellProfiler cell image analysis software 
(Broad Institute).  Unpaired two-tailed t tests were performed on data sets using 
GraphPad Prism 3.0 (GraphPad Software, Inc.). 
 
Cell-cycle analysis.  HCC1937/DR-GFP cells were serum-starved and infected with HD-
Ad vectors.  Cells were collected at 8, 16, 24, and 48 hrs after HD-Ad infection, fixed in 
70% ethanol, and cell-cycle distribution was analyzed for DNA content after staining 
with 5 µg/mL propidium iodide solution (0.1% TritonX-100/PBS with RNase) by FACS 
analysis using a Beckman Coulter XL-MC flow cytometer at the Massey Cancer Center 
Flow Cytometry and Imaging Core. 
 
Trypan Blue/FACS cell survival assay.  HCC1937/DR-GFP cells were infected with 
HD-Ad vectors on 100 mm dishes.  48 hrs post-infection, cells were trypsinized and 
250,000 cells were seeded onto 60 mm dishes.  24 hrs later cells were irradiated with 
doses of either 4 or 8 Gy or left unirradiated.  7 days post-irradiation, the total number of 
cells in each dish were collected and re-suspended in equal volumes of media.  Trypan 
Blue was added to the samples immediately prior to FACS analysis.  FACS analysis 
consisted of differentiating the side scatter profile (live cells) from the fluorescent 
(Trypan Blue stained dead cells) population using a Beckman Coulter XL-MC flow 
cytometer at the Massey Cancer Center Flow Cytometry and Imaging Core.  Surviving 
fractions were calculated by determining the number of live cells in each sample relative 
to untreated control sample.  Unpaired two-tailed t tests were performed on data sets 
using GraphPad Prism 3.0 (GraphPad Software, Inc.). 
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Chapter 4 
 
The BRCA1 S1387A mutant only partially increases the radiosurvival of HCC1937 
cells 
 
Introduction  
 
BRCA1 phosphorylation at serine 988 by CHK-2 has been implicated in DSB repair and 
BRCA1 sub-cellular localization (Zhang, Willers et al. 2004) (Okada and Ouchi 2003).  
However, it remains to be determined whether ATM/ATR targets within the SQ cluster 
region spanning amino acids 1241-1530 of BRCA1 also affect these processes.  Serine 
1387 within the SQ cluster is of particular interest as it is uniquely phosphorylated by 
ATM in response to IR and is involved in the intra-S phase checkpoint (Gatei, Zhou et al. 
2001) (Xu, O'Donnell et al. 2002).  We therefore sought to determine whether serine 
1387 phosphorylation might also affect DSB repair and BRCA1 sub-cellular localization.  
Here we report that expression of the BRCA1 S1387A mutant in HCC1937 cells only 
partially increases cell survival in response to IR compared to cells expressing wild-type 
BRCA1.  In addition, we present a possible mechanistic basis for this partial increase in 
radiosurvival using immunocytochemical analysis implicating a role for serine 1387 
phosphorylation in the sub-cellular localization of BRCA1 in response to IR.  Although 
the S1387A mutant alone did not have an effect on HRR levels compared to wild-type 
BRCA1, we show that serine 1387 phosphorylation in combination with the other SQ 
cluster serine ATM/ATR phosphorylation sites is involved in HRR.  These findings 
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reveal that BRCA1 SQ cluster serine phosphorylation in addition to serine 988 
phosphorylation is important for DSB repair. 
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Experimental Results  
 
BRCA1 S1387A only partially increases HCC1937 cell radiosurvival.  It has 
previously been reported that the re-introduction of full-length, wild-type BRCA1 into 
HCC1937 cells increases cell survival in response to IR (Scully, Ganesan et al. 1999).  
Our data supports this finding when HCC1937 cells were infected with the HD-Ad vector 
expressing wild-type BRCA1.  However, we found that expression of BRCA1 S1387A 
only partially increased the radiosurvival of HCC1937 cells compared to wild-type 
BRCA1 (Fig. 15-A).  This result was statistically significant when wild-type BRCA1 
infected cells were compared with S1387A mutant and vector control infected cells at 4 
Gy (P < 0.05 and 0.0008, respectively).  LacZ staining of infected cells demonstrated 
similar infection efficiencies (Fig. 15-B).   
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Figure 15.  BRCA1 S1387A only partially increases HCC1937 cell radiosurvival.  
HCC1937 cells were infected with HD-Ad vectors expressing vector control, wild-type 
BRCA1, or S1387A mutant.  (A) Survival of infected cells at doses of 0, 2, 4, 8, or 12 Gy 
following the addition of Alamar Blue five days post-irradiation.  Error bars represent the 
SEM of quadruplicate determinations.  (B) LacZ staining of infected cells. 
 
 
 
 
 49
BRCA1 S1387A shows aberrant sub-cellular localization in HCC1937 cells.  To 
investigate the basis for the differential effects of wild-type BRCA1 and the S1387A 
mutant on radiosurvival, immunocytochemical analysis of infected HCC1937 cells was 
performed.  Cells infected with the S1387A mutant virus showed a dramatic and 
surprising difference in the sub-cellular localization of BRCA1 protein in response to IR 
compared to cells infected with the wild-type BRCA1 virus (Fig. 16-A).  Whereas wild-
type BRCA1 was located in the nucleus after exposure to IR, the S1387A mutant was 
predominately cytoplasmic (Fig. 16-B).  In addition, unirradiated cells infected with 
either wild-type BRCA1, S1387A mutant, or vector control virus showed no significant 
BRCA1 staining.  This result suggests that the S1387A mutant displays impaired nuclear 
translocation in response to IR. 
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Figure 16.  BRCA1 S1387A is unable to translocate to the nucleus of irradiated 
HCC1937 cells.  Immunocytochemical analysis of BRCA1 sub-cellular localization in 
HCC1937 cells infected with HD-Ad vectors expressing vector control, wild-type 
BRCA1, or S1387A mutant or left uninfected.  (A) Cells were irradiated at doses of 0 or 
10 Gy and fixed 15 min later.  (B) Three representative images of wild-type BRCA1 and 
S1387A mutant sub-cellular localization at 10 Gy.  Red = BRCA1, Blue = DAPI. 
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BRCA1 serine 1387 phosphorylation in combination with other ATM/ATR 
phosphorylation sites is involved in homologous recombination repair.  Having 
established differences with the S1387A mutant compared to wild-type BRCA1 on cell 
survival and BRCA1 sub-cellular localization in response to IR, we next sought to 
determine what effect serine 1387 phosphorylation might have on HRR alone and in 
combination with the other BRCA1 SQ cluster serine ATM/ATR phosphorylation sites.  
In addition to the S1387A single mutant, we constructed a S1387/1423/1457/1524A 
quadruple mutant containing all the known SQ cluster serine ATM/ATR phosphorylation 
sites (Gatei, Zhou et al. 2001).  Whereas the S1387A mutant alone did not have an effect 
on HRR, the quadruple mutant resulted in HRR being reduced to the level seen in cells 
lacking functional BRCA1 (Fig. 17).  Altogether, these findings suggest that BRCA1 SQ 
cluster serine phosphorylation is involved in DSB repair and that inhibition of SQ cluster 
phosphorylation events in addition to serine 1387 is required to disrupt HRR.     
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Figure 17.  BRCA1 SQ cluster serine phosphorylation by ATM/ATR is involved in 
HRR.  HCC1937/DR-GFP cells were infected with HD-Ad vectors expressing vector 
control, BRCA1 wild-type, S1387A mutant, or S1387/1423/1457/1524A quadruple 
mutant, or left uninfected and analyzed for HRR/GFP events by FACS as in 9-A.   
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Chapter Summary  
 
Our finding that serine 1387 phosphorylation may play a role in BRCA1 nuclear 
import/export was surprising.  It is not clear from these studies whether BRCA1 S1387A 
is unable to enter the nucleus or if it is simply not retained in the nucleus.  However, 
because BRCA1 is phosphorylated on serine 1387 by ATM in the nucleus, the partial 
increase in radiosurvival of HCC1937 cells expressing the S1387A mutant supports the 
suggestion that phosphorylation of serine 1387 is involved in nuclear retention (Gatei, 
Scott et al. 2000).   
 
Immunocytochemical analysis of uninfected HCC1937 cells or cells infected with the 
vector control virus showed that most of the endogenous, truncated BRCA1 protein was 
also located around the nucleus in response to IR.  This is in line with the finding that the 
endogenous, truncated form of BRCA1 produced by HCC1937 cells is unable to localize 
into IR-induced nuclear foci (Rodriguez et al. 2004).  Endogenous protein is stained 
because the anti-BRCA1 antibody used recognizes an epitope in the N’ terminal region of 
BRCA1.  Interestingly, more of the ectopically-expressed BRCA1 protein was detectable 
in irradiated verses unirradiated cells.  This result might suggest that IR induces a 
conformational change in the BRCA1 protein itself or in BRCA1 protein complexes that 
allows the N’ terminal epitope to become more exposed.  In addition, IR might induce 
stability of BRCA1 protein.   
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This study finds that serine 1387 phosphorylation of BRCA1 is important for the 
radiosurvival of HCC1937 cells.  A previous report showed no significant difference 
between wild-type BRCA1 and the S1387A mutant in HCC1937 cell survival in response 
to IR (Xu, O'Donnell et al. 2002).  However, these studies expressed BRCA1 constructs 
in HCC1937 cells using plasmid vectors.  The HD-Ad vector-based system used in this 
study allows a more controlled expression of the BRCA1 constructs.  The HCC1937 cells 
are being transduced with an MOI of 1-2 in the present study.  This represents more 
physiologic levels of BRCA1 expression.  
 
We also found that the S1387A mutation alone was not sufficient to disrupt HRR.  
However, this mutation in combination with the loss of the other SQ cluster serine 
ATM/ATR phosphorylation sites did disrupt HRR.  Future experiments will need to 
determine the effect of the quadruple SQ cluster phosphorylation mutant on radiosurvival 
and BRCA1 sub-cellular localization.  In addition, other combinations of these SQ cluster 
serine mutants will also need to be examined to determine which specific serine residues 
are involved in various processes.   
 
The results presented here suggest a mechanistic basis for the partial increase in 
radiosurvival of HCC1937 cells expressing the S1387A mutant based on the ability of 
wild-type BRCA1 to enter and remain within the nucleus in response to DNA damage to 
help facilitate the repair response.  Interestingly, because BRCA1 S1387A did not have 
an effect on HRR, it is therefore possible that serine 1387 phosphorylation might be 
involved in non-homologous end-joining.  Future experiments will need to examine this 
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possibility.  Altogether, these findings suggest that in addition to serine 988 
phosphorylation, BRCA1 SQ cluster serine phosphorylation is also involved in DSB 
repair.  
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Chapter Methods 
 
Generation of HD-Ad vectors.  HD-Ad vectors expressing HA-BRCA1 wild-type and 
S1387A mutant were generated as follows: plasmids pcDNA3-HA-BRCA1 wild-type 
and S1387A (kindly provided by Bo Xu) were digested with MluI and BssHII and the 
HA-BRCA1 fragments ligated into the AscI site of the helper-dependent adenovirus (HD-
Ad) p∆28E4LacZ (Xu, O'Donnell et al. 2002).  The p∆28E4LacZ-HA-BRCA1 plasmids 
co-expressing HA-BRCA1 and a β-galactosidase (LacZ) reporter were digested with 
PmeI and crude virus stocks were obtained as described in Chapter 3.  HD-Ad vectors 
expressing HA-3XFLAG-BRCA1 S1387A and S1387/1423/1457/1524A mutants were 
generated as follows: plasmids pcDNA3(BssHII)-HA-3XFLAG-BRCA1 S1387A and 
S1387/1423A were generated from plasmids pcDNA3-HA-BRCA1 S1387A and 
S1387/1423A (kindly provided by Bo Xu) by swapping the BamHI XhoI fragments with 
pcDNA3(BssHII)-HA-3XFLAG-BRCA1 wild-type (Xu, O'Donnell et al. 2002).  The 
S1387/1423/1457/1524A quadruple mutant was generated from plasmid 
pcDNA3(BssHII)-HA-3XFLAG-BRCA1 S1387/1423A by sequential rounds of 
QuikChange site-directed mutagenesis (Stratagene) using primers 
GCAGTATTAACTGCACAGAAAAGTAGTG and 
CACTACTTTTCTGTGCAGTTAATACTGC to create the S1457A mutation and 
primers GAATAGAAACTACCCAGCTCAAGAGGAGCTC and 
GAGCTCCTCTTGAGCTGGGTAGTTTCTATTC to create the S1524A mutation.  The 
p∆28E4LacZ-HA-3XFLAG-BRCA1 plasmids and crude virus stocks were obtained from 
pcDNA3(BssHII)-HA-3XFLAG-BRCA1 plasmids as described in Chapter 3. 
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HCC1937 cell culture, irradiation, and survival.  HCC1937 cells were cultured in 
RPMI 1640 media (Cellgro) supplemented with 10% FBS (Gibco).  Cells at ~90% 
confluency were infected with HA-BRCA1 wild-type, S1387A mutant, or vector control 
virus.  48 hrs post-infection, cells were trysinized and seeded onto 96-well plates in 
quadruplicate.  24 hrs after seeding, cells were irradiated at doses of 0, 2, 4, 8, or 12 Gy 
using a 60Co irradiator.  Five days post-irradiation, cell survival was assessed by the 
addition of Alamar Blue (Serotec Ltd.) using a FLUOstar Optima plate reader (BMG 
Labtechnologies).  Unpaired two-tailed t tests were performed on data sets using 
GraphPad Prism 3.0 (GraphPad Software, Inc.).  Parallel infections were performed in 
which cells were fixed and stained for β-galactosidase expression with X-gal to score for 
relative infection efficiencies.                   
 
Immunocytochemistry.  HCC1937 cells were seeded onto chamber slides and infected 
with HA-BRCA1 wild-type, S1387A mutant, or vector control virus or left uninfected.  
48 hrs post-infection, cells were irradiated at doses of 0 or 10 Gy and fixed 15 min later 
with 3% paraformaldehyde.  Cells were then permeabilized using 0.5% TritonX-100 and 
immunostained using anti-BRCA1 antibody (Ab-1, Oncogene) at 1:100 dilution and 
Alexa Fluor 546 goat anti-mouse IgG antibody (Molecular Probes) at 1:500 dilution.  
Nuclei were visualized using Vectashield Mounting Media with DAPI (1.5 µg/mL).  
Samples were imaged using the 63X objective of a Zeiss LSM 510 Meta imaging system 
at the Massey Cancer Center Flow Cytometry and Imaging Core.   
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HRR/GFP DSB repair assay.  The HRR/GFP assay was performed as described in 
Chapter 3 using HD-Ad vectors expressing HA-3XFLAG-BRCA1.   
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Chapter 5:  Discussion  
 
Since the discovery of the BRCA1 gene 15 years ago much effort has been employed into 
discovering the functions of the BRCA1 protein.  These efforts have lead to the discovery 
that BRCA1 participates in a multitude of activities in the cell.  These activities range 
from cell-cycle and transcriptional regulation to DSB repair.  Despite the numerous 
activities and binding partners found to be associated with BRCA1, it still remains to be 
determined why mutations in the BRCA1 gene are specifically linked to breast and 
ovarian cancers.  Although the BRCA1 protein is fairly large in size spanning 1863 
amino acids, most cancer-causing mutations have been found to be associated with the N’ 
and C’ terminal domains, both of which are believed to be important in DSB repair 
(Couch and Weber 1996) (Shen and Vadgama 1999).  In addition to BRCA1, the BRCA2 
protein is also involved in the HRR pathway of DSB repair (Moynahan, Pierce et al. 
2001).  Thus, altered DSB repair may be a commonality in both BRCA1 and BRCA2 
associated breast and ovarian cancers.   
 
The BRCT domain of BRCA1 was an attractive target to study the role of BRCA1 in 
DSB repair because this domain binds to multiple proteins directly involved in the repair 
process.  The main focus of this work was therefore to determine how altered binding of 
repair factors to BRCA1 would impact DSB repair and specifically HRR.  In order to 
look at the effect of BRCA1 BRCT mutants on DSB repair, we generated BRCA1-
expressing helper-dependent “gutted” adenoviral vectors to express BRCA1 in breast 
cancer cell lines which are hard to transfect.  Besides having the ability to get transgene 
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expression in these cells, we could also have more control over the copy number than by 
plasmid transfection.  In addition, transient expression from virus allowed us to avoid the 
effects of clonal selection.  We next used these vectors to infect the BRCA1-defective 
human breast carcinoma cell line HCC1937 (Tomlinson, Chen et al. 1998).  We 
engineered these cells to have an integrated repair cassette that allowed us to score for 
HRR events by GFP expression when a DSB is created in the cassette by expression of 
the yeast I-SceI endonuclease (Pierce, Johnson et al. 1999).   
 
The results presented here suggest the surprising finding that altered BRCT binding 
enhances the HRR activity of BRCA1.  Interestingly, this enhancement did not confer an 
advantage to the radiosurvival of HCC1937 cells suggesting the increase in HRR is 
aberrant.  This result is in line with the previous finding that the naturally occurring 
BRCA1 BRCT mutation M1775R, which also disrupts CtIP binding, decreases the 
radiosurvival of HCC1937 cells (Varma, Brown et al. 2005) (Scully, Ganesan et al. 
1999).  However, how the M1775R mutant directly affects HRR has yet to be 
determined.   In addition, the data presented here suggest that the BRCA1 RING and 
BRCT domains must communicate for efficient HRR and that the RING domain has a 
dominant role over BRCT domain mediated phospho-protein interactions in the repair of 
DSBs by HRR.  Although another group recently found that the I26A ubiquitin ligase 
mutant used in our studies was not involved in HRR in embryonic stem cells, they 
attributed the ubiquitin ligase activity of BRCA1 toward BRCA1 stabilization (Reid et al. 
2008).  However, in our studies BRCA1 K1702M, which we showed to have increased 
ubiquitination, appeared to be less stable than wild-type BRCA1 and we did not observe 
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a major difference between BRCA1 wild-type and I26A mutant stabilization.  In addition, 
CtIP ubiquitination by BRCA1 suggests additional roles for BRCA1 ubiquitin ligase 
activity above and beyond stabilization (Yu, Fu et al. 2006).  Altogether, these findings 
suggest a hierarchal regulation of BRCA1 function in the repair of DSBs by HRR and an 
as yet undefined mechanism where mutations in the BRCA1 BRCT domain might 
contribute to the development of breast and ovarian cancers through uncontrolled 
homologous recombination which is aberrant.   
 
We also examined the effect of BRCA1 K1702M on HRR in U87 glioma cells which 
express endogenous, wild-type BRCA1.  Having verified that BRCA1 is important for 
HRR in these cells by shRNA-mediated knock-down of endogenous BRCA1, we found 
that over-expression of BRCA1 K1702M resulted in a 3-fold reduction in HRR compared 
to cells over-expressing wild-type BRCA1 or vector control.  These results suggest that 
the K1702M mutant has a dominant-negative effect in cells endogenously expressing 
wild-type BRCA1.  This reduction in HRR might result if the hyper-recombinogenic 
phenotype is breast cancer cell specific or does not occur in cells expressing wild-type 
BRCA1.  Because wild-type BRCA1 over-expression of ~20-fold compared to 
endogenous BRCA1 did not increase HRR levels compared to vector control suggests the 
later and that interference with endogenous BRCA1 disrupts the balance of HRR in these 
types of cells.  However, future studies will need to determine the breast cancer cell 
specificity of the hyper-recombinogenic phenotype by over-expressing  BRCA1 K1702M 
in MCF-7 breast carcinoma cells which express one allele of wild-type BRCA1 (Holt et 
al. 1996).  
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So how might BRCA1 BRCT mutations mechanistically enhance HRR in breast cancer 
cells?  One possibility is that BRCA1 is known to associate with the Mre11-RAD50-
NBS1 (MRN) complex and it was recently shown that BRCA1, CtIP, and NBS1 
associate in a complex in a cell-cycle dependent manner with NBS1 interacting with the 
N’ terminus of BRCA1 (Zhong et al. 1999) (Chen, Nievera et al. 2008).  Although the 
MRN complex itself has been reported not to have the 5’→3’ exonuclease activity 
necessary to generate the 3’ overhangs utilized for HRR, CtIP may regulate other 
nucleases important in this process (Paull and Gellert 1998) (Trujillo et al. 1998).  
However, it was recently reported that the MRN homologue in archaea has 5’→3’ 
exonuclease activity and the CtIP yeast homologue Sae2 has endonuclease activity 
(Lengsfeld et al. 2007) (Hopkins and Paull 2008).  These findings suggest that if CtIP 
binds less to BRCA1 this could result in more extensive exonuclease activity by MRN if 
the role of CtIP is to limit the length of resection by making an endonucleolyic cut in the 
DNA ahead of resection.  This would in turn lead to more single-stranded DNA available 
for HRR (Fig. 18).   
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Figure 18.  Proposed mechanism for hyper-recombinogenic phenotype of BRCA1 
BRCT mutants.  (A) Following a DSB induced by DNA-damaging agents such as IR or 
at stalled replication forks, BRCA1 associates with the Mre11-RAD50-NBS1 (MRN) 
complex through NBS1 interacting with the N’ terminus of BRCA1 and with CtIP which 
interacts with the C’ terminus.  The DSB is then resected in the 5’ → 3’ direction 
yielding 3’ overhangs coated with the single-standed DNA binding protein RPA which 
are subsequently replaced with the RAD51 recombinase via BRCA2.  To limit the length 
of resection, CtIP might serve as an endonuclease that creates a single-stranded break in 
the DNA ahead of resection.  (B) BRCA1 BRCT mutants (BRCA1BRCTµ) result in 
decreased CtIP binding and loss of its associated endonuclease activity that allows 
excessive resection leading to more extensive 3’ overhangs and associated RAD51 
binding resulting in increased HRR.   
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In support of this mechanism, our RAD51 data showed dramatic increases in BRCA1 
K1702M induced RAD51 foci and nuclear staining by immunocytochemistry with or 
without irradiation and increased RAD51 dimerization by western blotting.  This data 
supports the notion that more single-stranded DNA is produced by BRCA1 K1702M 
thereby allowing more RAD51 to bind.  Although we did not observe as dramatic an 
increase in RAD51 levels by western blotting compared to what we observed with 
immunocytochemistry, we expect the overall small percentage of dimers to represent the 
4-7% of super bright cells we observed.  These super bright cells might represent a small 
fraction of cells with extensive single-stranded DNA in a cell-cycle phase conducive of 
optimal HRR. 
 
Alternatively, another possibility is that the interaction of BRCA1 with CtIP may not 
serve to facilitate DSB repair as it has been suggested that binding of CtIP to BRCA1 
may serve to repress BRCA1 transcriptional activity and that the dissociation of this 
interaction upon DNA damage would lead to active repair proteins (Li, Chen et al. 1999) 
(Li et al. 2000).  It has also been shown that CtIP silencing in breast cancer cell lines 
confers resistance to the anti-estrogen tamoxifen which also suggests a regulatory 
function of CtIP on BRCA1 since this interaction might be responsible for BRCA1-
mediated inhibition of estrogen receptor transcriptional activity that would, in turn, allow 
for more effective tamoxifen treatment (Wu et al. 2007) (Zheng et al. 2001).  Disruption 
of the BRCA1-CtIP interaction could also explain why we see cell-cycle arrest in G2/M 
if unbound CtIP is available to arrest the cells (Yu, Fu et al. 2006).  Further experiments 
will be needed to determine the exact mechanistic basis of increased HRR and determine 
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whether other mutations in the BRCT domain of BRCA1 that disrupt CtIP binding such 
as the naturally occurring M1775R mutant have the same phenotype as BRCA1 
K1702M.  Future experiments will also need to determine the effect of increased HRR 
mediated by BRCA1 BRCT mutants on non-homologous end-joining activity.   
 
The results presented here should help determine how BRCA1 BRCT mutations might 
contribute to the development of breast and ovarian cancers.  These results also have 
implications for the development of BRCA1 BRCT inhibitors and suggest such inhibitors 
might actually stimulate BRCA1 activity leading to cell-cycle arrest and the decreased 
radiosurvival of breast cancer cells.  However, the finding that BRCA1 RING domain 
associated ubiquitin ligase activity seems to have a dominate role over the BRCT domain 
mediated increase in HRR suggests that inhibitors of the ubiquitin ligase activity of 
BRCA1 might be a better target to disrupt the DSB repair capacity of this protein when 
used in combination with radiation therapy. 
 
Our studies on the role of BRCA1 SQ cluster serine phosphorylation in DSB repair 
revealed that serine 1387 phosphorylation affects BRCA1 sub-cellular localization and 
the radiosurvival of HCC1937 cells.  In addition, we show that serine 1387 
phosphorylation in combination with the other SQ cluster serine ATM/ATR 
phosphorylation sites is involved in HRR.  Because BRCA1 is localized to the site of 
DSBs via the BRCA1 BRCT/CCDC98/RAP80 interaction where BRCA1 is 
phosphorylated by ATM, differential BRCA1 phosphorylations at this stage may be the 
critical event which dictates future cellular events in the DNA damage response such as 
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cell-cycle arrest and DSB repair pathway choice (Sobhian, Shao et al. 2007) (Gatei, Scott 
et al. 2000).  Thus, serine 988 phosphorylation might influence DSB repair pathway 
choice while SQ cluster phosphorylation events might trigger conformational changes in 
BRCA1 leading to different BRCT domain binding partners.  Serine 1387 
phosphorylation might trigger binding with BACH1 since both of these are involved in S 
phase events whereas serine 1423/1524 phosphorylation might trigger CtIP binding 
which are both involved in G2/M cell-cycle arrest (Xu, O'Donnell et al. 2002) (Xu, Kim 
et al. 2001) (Yu, Fu et al. 2006) (Kumaraswamy and Shiekhattar 2007).  In addition, 
these SQ cluster phosphorylation events might indirectly influence alternative binding 
through cell-cycle dependent phosphorylation of BACH1 and CtIP which occurs during 
the S and G2 phases, respectively (Yu and Chen 2004) (Yu, Chini et al. 2003) .    
 
Future studies will be needed to determine if BRCA1 phosphorylation triggers the initial 
events involved in the DSB repair activity of BRCA1.  The current work suggests 
BRCA1 RING domain associated ubiquitin ligase activity is upstream of BRCT domain 
mediated HRR activity.  However, BRCA1 phosphorylation events might be upstream of 
RING domain mediated activity.  If so, these findings could lead to a hierarchal model 
where BRCA1 phosphorylation leads to the activation of BRCA1 ubiquitin ligase activity 
that is critical for CtIP mediated repair processes.  Future studies will be needed to 
determine if this is the order of events as these findings could lead to the development of 
multiple strategies of modulating BRCA1 function in response to DNA damage.  
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